||6R01CA078938-04 Interpret this number
||City Of Hope/Beckman Research Institute
||Bone Marrow Transplant (BMT) Survivors Study
DESCRIPTION (Adapted from the Applicant's Abstract): Through collaboration
between the City of Hope National Medical Center and the University of
Minnesota, we propose to define a cohort of patients who have undergone bone
marrow transplantation (BMT) at these two centers and have survived at least
two years, regardless of their current life-status. The objective of this Bone
Marrow Transplant Survivors' Study (BMT-SS) is to establish and characterize a
cohort of 1,894 pediatric and adult long-term survivors of BMT, to address the
following aims: i) Identify detailed information on the incidence and risk
factors for cardiopulmonary disease, endocrine abnormalities, fertility, and
subsequent cancers; ii) Describe the impact of the above complications on the
quality of life in this cohort of BMT survivors; iii) Characterize the
health-related behaviors and patterns of medical care in survivors. The
methodology involves a mailed survey of two questionnaires: (i) the BMT-SS
Questionnaire, a validated, self-administered (subjects > 18 years) or
parent-administered (subjects < 18 years) questionnaire addressing all
potential long-term complications in this group of survivors; and (ii) the City
of Hope Quality of Life Questionnaire for Bone Marrow Transplantation
(BMT-QOL), (subjects > 18 years) or the Child's Health Questionnaire (subjects
< 18 years). A frequency-matched sample of 500 siblings will be enrolled into
the study. The sibling controls will provide: i) the ability to make direct
comparisons with the survivors, ii) data on outcomes in a noncancer population,
not available from other sources (vital statistics, NHIS, etc.). For selected
reported outcomes (second cancers, etc.) we will conduct additional analyses
using a nested case-control approach. This will allow us to collect additional,
more extensive data on survivors experiencing the outcomes (cases), and those
not experiencing the outcome (controls). The cohort will be of sufficient size
and heterogeneity with respect to primary malignancy, type of transplant age at
transplant, and ethnic background to allow for the study of endpoints of
interest in this population. The results will provide important information
that may be used in the design of future therapeutic strategies and/or
interventions to decrease the occurrence of deleterious effects related to
treatment exposures and host factors. Having such a cohort in place will give
us the opportunity in the future to continue to collect information on major
study end-points (e.g., second cancers, births, cardiac complications, etc.)
that may have occurred since the completion of the initial questionnaire.
Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study.
Ness KK, Bhatia S, Baker KS, Francisco L, Carter A, Forman SJ, Robison LL, Rosenthal J, Gurney JG
Arch Pediatr Adolesc Med, 2005 Aug;159(8), p. 706-13.
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.
Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L, McGlave PB, Robison LL, Snyder DS, Weisdorf DJ, Bhatia S
Blood, 2004 Sep 15;104(6), p. 1898-906.
2004 Jun 1.